drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01156 | DB04844 | 593 | 843 | [
"DDInter252",
"DDInter1778"
] | Bupropion | Tetrabenazine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
593,
25,
843
]
],
[
[
593,
64,
479
],
[
479,
40,
843
]
],
[
[
593,
6,
12523
],
[
12523,
45,
843
]
],
[
[
593,
21,
28698
],
[
28698,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (C... | Bupropion may lead to a major life threatening interaction when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Bupropion (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Bupropion (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) i... |
DB00916 | DB01227 | 112 | 1,301 | [
"DDInter1202",
"DDInter1043"
] | Metronidazole | Levacetylmethadol | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Minor | 0 | [
[
[
112,
23,
1301
]
],
[
[
112,
62,
494
],
[
494,
1,
1301
]
],
[
[
112,
6,
8374
],
[
8374,
45,
1301
]
],
[
[
112,
23,
688
],
[
688,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Disopyramide"
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levacetylmethadol (Compound)
Metronidazole may cause a minor interaction ... |
DB08870 | DB09098 | 850 | 98 | [
"DDInter228",
"DDInter1700"
] | Brentuximab vedotin | Somatrem | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
850,
24,
98
]
],
[
[
850,
63,
168
],
[
168,
23,
98
]
],
[
[
850,
63,
671
],
[
671,
24,
98
]
],
[
[
850,
24,
159
],
[
159,
63,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Fluvast... |
DB00443 | DB01263 | 251 | 859 | [
"DDInter195",
"DDInter1494"
] | Betamethasone | Posaconazole | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
251,
24,
859
]
],
[
[
251,
6,
4973
],
[
4973,
45,
859
]
],
[
[
251,
21,
28762
],
[
28762,
60,
859
]
],
[
[
251,
63,
1101
],
[
1101,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compo... | Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Betamethasone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene... |
DB00877 | DB11757 | 629 | 960 | [
"DDInter1678",
"DDInter994"
] | Sirolimus | Istradefylline | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
629,
24,
960
]
],
[
[
629,
63,
134
],
[
134,
24,
960
]
],
[
[
629,
24,
86
],
[
86,
24,
960
]
],
[
[
629,
64,
600
],
[
600,
24,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Mi... |
DB00620 | DB08904 | 175 | 375 | [
"DDInter1855",
"DDInter342"
] | Triamcinolone | Certolizumab pegol | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
175,
25,
375
]
],
[
[
175,
62,
1461
],
[
1461,
23,
375
]
],
[
[
175,
23,
1193
],
[
1193,
62,
375
]
],
[
[
175,
24,
200
],
[
200,
... | [
[
[
"Triamcinolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate ... |
DB00675 | DB01142 | 888 | 1,264 | [
"DDInter1744",
"DDInter593"
] | Tamoxifen | Doxepin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
888,
24,
1264
]
],
[
[
888,
74,
508
],
[
508,
24,
1264
]
],
[
[
888,
24,
401
],
[
401,
24,
1264
]
],
[
[
888,
1,
832
],
[
832,
2... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Tamoxifen (Compound) resembles Promazine (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Tamoxifen may cause a moderate interaction that could exacerba... |
DB01072 | DB06203 | 915 | 1,002 | [
"DDInter129",
"DDInter51"
] | Atazanavir | Alogliptin | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
915,
24,
1002
]
],
[
[
915,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
915,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
915,
21,
28873
],
[
28873,... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Atazanavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Atazanavir (Compound) causes Pancreatitis (Side Effect) and Panc... |
DB11642 | DB14568 | 938 | 982 | [
"DDInter1480",
"DDInter1000"
] | Pitolisant | Ivosidenib | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
938,
25,
982
]
],
[
[
938,
62,
112
],
[
112,
23,
982
]
],
[
[
938,
63,
543
],
[
543,
24,
982
]
],
[
[
938,
24,
405
],
[
405,
24,... | [
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Pitolisant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lope... |
DB00222 | DB00860 | 245 | 891 | [
"DDInter825",
"DDInter1513"
] | Glimepiride | Prednisolone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
245,
24,
891
]
],
[
[
245,
24,
989
],
[
989,
1,
891
]
],
[
[
245,
24,
175
],
[
175,
40,
891
]
],
[
[
245,
24,
1561
],
[
1561,
24... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Progesterone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Prednisolone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Predniso... |
DB00005 | DB00682 | 1,057 | 126 | [
"DDInter687",
"DDInter1951"
] | Etanercept | Warfarin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1057,
24,
126
]
],
[
[
1057,
24,
362
],
[
362,
24,
126
]
],
[
[
1057,
25,
168
],
[
168,
23,
126
]
],
[
[
1057,
24,
671
],
[
671,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Etanercept may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a mi... |
DB00252 | DB04845 | 362 | 309 | [
"DDInter1460",
"DDInter1001"
] | Phenytoin | Ixabepilone | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
362,
24,
309
]
],
[
[
362,
6,
8374
],
[
8374,
45,
309
]
],
[
[
362,
21,
28736
],
[
28736,
60,
309
]
],
[
[
362,
24,
60
],
[
60,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Phenytoin (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and... |
DB00238 | DB09330 | 188 | 985 | [
"DDInter1285",
"DDInter1352"
] | Nevirapine | Osimertinib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
188,
24,
985
]
],
[
[
188,
62,
168
],
[
168,
23,
985
]
],
[
[
188,
23,
608
],
[
608,
23,
985
]
],
[
[
188,
24,
1478
],
[
1478,
2... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Nevirapine may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine ma... |
DB00674 | DB01075 | 1,516 | 1,376 | [
"DDInter802",
"DDInter569"
] | Galantamine | Diphenhydramine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1516,
24,
1376
]
],
[
[
1516,
63,
11
],
[
11,
1,
1376
]
],
[
[
1516,
63,
128
],
[
128,
24,
1376
]
],
[
[
1516,
24,
832
],
[
832,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate... |
DB01041 | DB11921 | 770 | 1,019 | [
"DDInter1789",
"DDInter492"
] | Thalidomide | Deflazacort | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
770,
25,
1019
]
],
[
[
770,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
770,
25,
192
],
[
192,
24,
1019
]
],
[
[
770,
24,
270
],
[
270,
... | [
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazi... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Thalidomide may lead to a major life threatening interaction when taken with Esterified estrogens and Esterified e... |
DB09073 | DB14568 | 951 | 982 | [
"DDInter1379",
"DDInter1000"
] | Palbociclib | Ivosidenib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
951,
24,
982
]
],
[
[
951,
62,
271
],
[
271,
23,
982
]
],
[
[
951,
63,
1101
],
[
1101,
23,
982
]
],
[
[
951,
64,
976
],
[
976,
2... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Palbociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarote... |
DB00393 | DB01142 | 854 | 1,264 | [
"DDInter1295",
"DDInter593"
] | Nimodipine | Doxepin | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
854,
24,
1264
]
],
[
[
854,
24,
401
],
[
401,
24,
1264
]
],
[
[
854,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
854,
21,
28954
],
[
28954,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Nimodipine (Compound... |
DB05316 | DB12245 | 749 | 823 | [
"DDInter1467",
"DDInter1863"
] | Pimavanserin | Triclabendazole | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
749,
24,
823
]
],
[
[
749,
62,
112
],
[
112,
23,
823
]
],
[
[
749,
63,
1010
],
[
1010,
24,
823
]
],
[
[
749,
24,
28
],
[
28,
24,... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Pimavanserin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]... | Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine... |
DB00398 | DB01015 | 79 | 1,247 | [
"DDInter1702",
"DDInter1724"
] | Sorafenib | Sulfamethoxazole | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Minor | 0 | [
[
[
79,
23,
1247
]
],
[
[
79,
6,
3486
],
[
3486,
45,
1247
]
],
[
[
79,
7,
9900
],
[
9900,
46,
1247
]
],
[
[
79,
18,
1918
],
[
1918,
... | [
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Sorafenib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound)
Sorafenib (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Sulfamethoxazole (Compound)
Sorafenib (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Sulfamethoxazole (Compound)... |
DB00496 | DB09291 | 194 | 741 | [
"DDInter480",
"DDInter1615"
] | Darifenacin | Rolapitant | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
194,
24,
741
]
],
[
[
194,
24,
506
],
[
506,
24,
741
]
],
[
[
194,
24,
159
],
[
159,
63,
741
]
],
[
[
194,
63,
353
],
[
353,
24,... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Larotre... |
DB08816 | DB11071 | 578 | 1,004 | [
"DDInter1802",
"DDInter1449"
] | Ticagrelor | Phenyl salicylate | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
578,
24,
1004
]
],
[
[
578,
64,
500
],
[
500,
24,
1004
]
],
[
[
578,
25,
498
],
[
498,
24,
1004
]
],
[
[
578,
24,
235
],
[
235,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Eno... | Ticagrelor may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Ticagrelor may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate i... |
DB00872 | DB00959 | 1,080 | 1,486 | [
"DDInter438",
"DDInter1191"
] | Conivaptan | Methylprednisolone | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Major | 2 | [
[
[
1080,
25,
1486
]
],
[
[
1080,
64,
175
],
[
175,
40,
1486
]
],
[
[
1080,
63,
167
],
[
167,
1,
1486
]
],
[
[
1080,
24,
1220
],
[
1220,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone"... | Conivaptan may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisol... |
DB00209 | DB00512 | 352 | 91 | [
"DDInter1886",
"DDInter1916"
] | Trospium | Vancomycin | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Moderate | 1 | [
[
[
352,
24,
91
]
],
[
[
352,
21,
29118
],
[
29118,
60,
91
]
],
[
[
352,
24,
1579
],
[
1579,
63,
91
]
],
[
[
352,
24,
1645
],
[
1645,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
]
],
[
[
"Trospium",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caus... | Trospium (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Vancomycin (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium may cause a moderate interaction that could exacerbate diseases when taken with Vanco... |
DB01186 | DB01246 | 107 | 820 | [
"DDInter1430",
"DDInter45"
] | Pergolide | Alimemazine | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
107,
24,
820
]
],
[
[
107,
63,
104
],
[
104,
40,
820
]
],
[
[
107,
63,
401
],
[
401,
24,
820
]
],
[
[
107,
24,
649
],
[
649,
1,
... | [
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB00063 | DB08896 | 366 | 292 | [
"DDInter659",
"DDInter1576"
] | Eptifibatide | Regorafenib | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
366,
25,
292
]
],
[
[
366,
24,
643
],
[
643,
24,
292
]
],
[
[
366,
24,
41
],
[
41,
63,
292
]
],
[
[
366,
25,
553
],
[
553,
25,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"D... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Levomiln... |
DB00197 | DB00668 | 1,324 | 874 | [
"DDInter1881",
"DDInter652"
] | Troglitazone | Epinephrine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Moderate | 1 | [
[
[
1324,
24,
874
]
],
[
[
1324,
24,
1636
],
[
1636,
1,
874
]
],
[
[
1324,
24,
688
],
[
688,
63,
874
]
],
[
[
1324,
24,
1399
],
[
1399,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction... |
DB00030 | DB14731 | 1,685 | 1,518 | [
"DDInter934",
"DDInter1741"
] | Insulin human | Tagraxofusp | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
1685,
24,
1518
]
],
[
[
1685,
24,
123
],
[
123,
24,
1518
]
],
[
[
1685,
24,
695
],
[
695,
25,
1518
]
],
[
[
1685,
24,
123
],
[
123,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Cl... |
DB06663 | DB09122 | 1,154 | 1,613 | [
"DDInter1398",
"DDInter1409"
] | Pasireotide | Peginterferon beta-1a | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1154,
24,
1613
]
],
[
[
1154,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
1154,
24,
975
],
[
975,
63,
1613
]
],
[
[
1154,
64,
600
],
[
600,
... | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
... | Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lurbin... |
DB00468 | DB01611 | 1,424 | 1,487 | [
"DDInter1557",
"DDInter893"
] | Quinine | Hydroxychloroquine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
1424,
25,
1487
]
],
[
[
1424,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
1424,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
1424,
21,
28658
],
[
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaqui... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Quinine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Quinine (Compound) caus... |
DB01261 | DB04908 | 170 | 1,671 | [
"DDInter1679",
"DDInter741"
] | Sitagliptin | Flibanserin | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
170,
24,
1671
]
],
[
[
170,
63,
168
],
[
168,
23,
1671
]
],
[
[
170,
24,
741
],
[
741,
63,
1671
]
],
[
[
170,
63,
303
],
[
303,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Flibanserin
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolap... |
DB00395 | DB00405 | 210 | 128 | [
"DDInter301",
"DDInter517"
] | Carisoprodol | Dexbrompheniramine | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
210,
24,
128
]
],
[
[
210,
24,
662
],
[
662,
63,
128
]
],
[
[
210,
64,
475
],
[
475,
24,
128
]
],
[
[
210,
63,
701
],
[
701,
24,... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
... | Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Carisoprodol may lead to a major life threatening interaction when taken with Morphine and Morph... |
DB09498 | DB11952 | 810 | 800 | [
"DDInter1715",
"DDInter612"
] | Strontium chloride Sr-89 | Duvelisib | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
810,
24,
800
]
],
[
[
810,
63,
310
],
[
310,
24,
800
]
],
[
[
810,
24,
564
],
[
564,
63,
800
]
],
[
[
810,
24,
351
],
[
351,
24,... | [
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when tak... |
DB01259 | DB09122 | 392 | 1,613 | [
"DDInter1024",
"DDInter1409"
] | Lapatinib | Peginterferon beta-1a | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
392,
24,
1613
]
],
[
[
392,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
392,
63,
152
],
[
152,
24,
1613
]
],
[
[
392,
24,
975
],
[
975,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bosentan a... |
DB00011 | DB00609 | 1,451 | 595 | [
"DDInter944",
"DDInter694"
] | Interferon alfa-n1 | Ethionamide | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Moderate | 1 | [
[
[
1451,
24,
595
]
],
[
[
1451,
24,
372
],
[
372,
63,
595
]
],
[
[
1451,
63,
1057
],
[
1057,
24,
595
]
],
[
[
1451,
24,
597
],
[
597,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabin... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Et... |
DB06608 | DB09112 | 1,185 | 1,455 | [
"DDInter1739",
"DDInter1306"
] | Tafenoquine | Nitrous acid | Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoq... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Major | 2 | [
[
[
1185,
25,
1455
]
],
[
[
1185,
63,
1364
],
[
1364,
24,
1455
]
],
[
[
1185,
64,
490
],
[
490,
25,
1455
]
],
[
[
1185,
63,
10
],
[
10,
... | [
[
[
"Tafenoquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Tafenoquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
],
[
"Guanfa... | Tafenoquine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Tafenoquine may lead to a major life threatening interaction when taken with Prilocaine and Prilocaine may le... |
DB00526 | DB06688 | 1,555 | 1,430 | [
"DDInter1355",
"DDInter1677"
] | Oxaliplatin | Sipuleucel-T | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1555,
24,
1430
]
],
[
[
1555,
24,
51
],
[
51,
24,
1430
]
],
[
[
1555,
25,
869
],
[
869,
24,
1430
]
],
[
[
1555,
25,
676
],
[
676,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Oxaliplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may ... |
DB08881 | DB11652 | 868 | 1,155 | [
"DDInter1925",
"DDInter1891"
] | Vemurafenib | Tucatinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
868,
24,
1155
]
],
[
[
868,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
868,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
868,
24,
659
],
[
659,
... | [
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Vemurafenib may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moder... |
DB00313 | DB01124 | 556 | 1,411 | [
"DDInter1913",
"DDInter1828"
] | Valproic acid | Tolbutamide | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Minor | 0 | [
[
[
556,
23,
1411
]
],
[
[
556,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
556,
21,
28828
],
[
28828,
60,
1411
]
],
[
[
556,
23,
1475
],
[
147... | [
[
[
"Valproic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Comp... | Valproic acid (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Valproic acid (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolbutamide (Compound)
Valproic acid may cause a minor interaction that can limit clinical ... |
DB06168 | DB06228 | 1,531 | 792 | [
"DDInter281",
"DDInter1609"
] | Canakinumab | Rivaroxaban | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
1531,
24,
792
]
],
[
[
1531,
63,
453
],
[
453,
40,
792
]
],
[
[
1531,
24,
1303
],
[
1303,
63,
792
]
],
[
[
1531,
63,
1683
],
[
1683,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
],
[
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid (Compound) resembles Rivaroxaban (Compound)
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab and Guselkumab may cause a moderate interaction that coul... |
DB00900 | DB06273 | 45 | 980 | [
"DDInter544",
"DDInter1824"
] | Didanosine | Tocilizumab | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
45,
24,
980
]
],
[
[
45,
24,
309
],
[
309,
24,
980
]
],
[
[
45,
24,
850
],
[
850,
63,
980
]
],
[
[
45,
63,
467
],
[
467,
24,
... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
... | Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedoti... |
DB00572 | DB00981 | 85 | 1,528 | [
"DDInter136",
"DDInter1462"
] | Atropine | Physostigmine | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
85,
24,
1528
]
],
[
[
85,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
85,
24,
1592
],
[
1592,
63,
1528
]
],
[
[
85,
63,
508
],
[
508,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Atropine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is cau... | Atropine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol and Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Physosti... |
DB01294 | DB06605 | 266 | 1,409 | [
"DDInter215",
"DDInter108"
] | Bismuth subsalicylate | Apixaban | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
266,
24,
1409
]
],
[
[
266,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
266,
63,
1039
],
[
1039,
24,
1409
]
],
[
[
266,
24,
235
],
[
235,
... | [
[
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Bismuth subsalicylate",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u}... | Bismuth subsalicylate (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate ... |
DB00048 | DB00759 | 1,595 | 1,620 | [
"DDInter435",
"DDInter1783"
] | Collagenase clostridium histolyticum | Tetracycline | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
1595,
24,
1620
]
],
[
[
1595,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
1595,
24,
126
],
[
126,
24,
1620
]
],
[
[
1595,
24,
279
],
[
279,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases wh... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Warfari... |
DB00087 | DB08885 | 599 | 363 | [
"DDInter41",
"DDInter33"
] | Alemtuzumab | Aflibercept | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Moderate | 1 | [
[
[
599,
24,
363
]
],
[
[
599,
24,
1531
],
[
1531,
24,
363
]
],
[
[
599,
24,
151
],
[
151,
63,
363
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aflibercept"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A viru... |
DB04861 | DB13142 | 1,592 | 841 | [
"DDInter1271",
"DDInter274"
] | Nebivolol | Calcium glubionate anhydrous | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1592,
24,
841
]
],
[
[
1592,
63,
1053
],
[
1053,
23,
255
],
[
255,
24,
841
]
],
[
[
1592,
63,
1053
],
[
1053,
24,
762
],
[
762,
24,
... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazin... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium glub... |
DB04837 | DB09061 | 649 | 1,627 | [
"DDInter407",
"DDInter284"
] | Clofedanol | Cannabidiol | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
649,
24,
1627
]
],
[
[
649,
1,
888
],
[
888,
24,
1627
]
],
[
[
649,
63,
1594
],
[
1594,
24,
1627
]
],
[
[
649,
74,
662
],
[
662,
... | [
[
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate... | Clofedanol (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could ... |
DB00081 | DB15035 | 273 | 503 | [
"DDInter1838",
"DDInter1959"
] | Tositumomab | Zanubrutinib | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Major | 2 | [
[
[
273,
25,
503
]
],
[
[
273,
24,
222
],
[
222,
24,
503
]
],
[
[
273,
63,
1257
],
[
1257,
24,
503
]
],
[
[
273,
25,
676
],
[
676,
6... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibut... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim a... |
DB00327 | DB01105 | 421 | 222 | [
"DDInter890",
"DDInter1665"
] | Hydromorphone | Sibutramine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
421,
24,
222
]
],
[
[
421,
6,
8374
],
[
8374,
45,
222
]
],
[
[
421,
21,
28852
],
[
28852,
60,
222
]
],
[
[
421,
24,
752
],
[
752,
... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Hydromorphone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Hydromorphone (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Cimeti... |
DB00461 | DB01067 | 598 | 959 | [
"DDInter1254",
"DDInter826"
] | Nabumetone | Glipizide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
598,
24,
959
]
],
[
[
598,
63,
245
],
[
245,
40,
959
]
],
[
[
598,
24,
1411
],
[
1411,
1,
959
]
],
[
[
598,
21,
29442
],
[
29442,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB01149 | DB08896 | 851 | 292 | [
"DDInter1274",
"DDInter1576"
] | Nefazodone | Regorafenib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
851,
24,
292
]
],
[
[
851,
6,
8374
],
[
8374,
45,
292
]
],
[
[
851,
21,
29276
],
[
29276,
60,
292
]
],
[
[
851,
25,
1135
],
[
1135,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nefazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)
Nefazodone (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Regorafenib (Compound)
Nefazodone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may ... |
DB00850 | DB09472 | 1,630 | 1,383 | [
"DDInter1432",
"DDInter1693"
] | Perphenazine | Sodium sulfate | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1630,
24,
1383
]
],
[
[
1630,
24,
609
],
[
609,
24,
1383
]
],
[
[
1630,
1,
146
],
[
146,
24,
1383
]
],
[
[
1630,
25,
1311
],
[
1311,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Perphenazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate in... |
DB00026 | DB00694 | 1,184 | 51 | [
"DDInter94",
"DDInter485"
] | Anakinra | Daunorubicin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1184,
24,
51
]
],
[
[
1184,
24,
1430
],
[
1430,
63,
51
]
],
[
[
1184,
24,
134
],
[
134,
24,
51
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vin... |
DB01082 | DB14761 | 1,448 | 242 | [
"DDInter1713",
"DDInter1578"
] | Streptomycin | Remdesivir | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1448,
24,
242
]
],
[
[
1448,
63,
1512
],
[
1512,
24,
242
]
],
[
[
1448,
64,
629
],
[
629,
24,
242
]
],
[
[
1448,
24,
1532
],
[
1532,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Streptomycin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may caus... |
DB00365 | DB00468 | 839 | 1,424 | [
"DDInter842",
"DDInter1557"
] | Grepafloxacin | Quinine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Major | 2 | [
[
[
839,
25,
1424
]
],
[
[
839,
23,
112
],
[
112,
62,
1424
]
],
[
[
839,
25,
1254
],
[
1254,
63,
1424
]
],
[
[
839,
24,
480
],
[
480,
... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Grepafloxacin may lead to a major life threatening interaction when taken with Insulin glulisine and Insulin g... |
DB00679 | DB01611 | 684 | 1,487 | [
"DDInter1796",
"DDInter893"
] | Thioridazine | Hydroxychloroquine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
684,
25,
1487
]
],
[
[
684,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
684,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
684,
7,
9853
],
[
9853,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Thioridazine may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Thioridazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Thioridazine (Compound) upre... |
DB00857 | DB11901 | 1,387 | 913 | [
"DDInter1768",
"DDInter107"
] | Terbinafine | Apalutamide | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1387,
24,
913
]
],
[
[
1387,
24,
279
],
[
279,
24,
913
]
],
[
[
1387,
63,
600
],
[
600,
24,
913
]
],
[
[
1387,
64,
888
],
[
888,
... | [
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and ... |
DB00005 | DB09312 | 1,057 | 967 | [
"DDInter687",
"DDInter106"
] | Etanercept | Antithymocyte immunoglobulin (rabbit) | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Major | 2 | [
[
[
1057,
25,
967
]
],
[
[
1057,
23,
1193
],
[
1193,
62,
967
]
],
[
[
1057,
25,
1683
],
[
1683,
24,
967
]
],
[
[
1057,
25,
1531
],
[
1531,... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
... | Etanercept may lead to a major life threatening interaction when taken with Antilymphocyte immunoglobulin (horse)
Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antil... |
DB00497 | DB08881 | 828 | 868 | [
"DDInter1366",
"DDInter1925"
] | Oxycodone | Vemurafenib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
828,
24,
868
]
],
[
[
828,
6,
8374
],
[
8374,
45,
868
]
],
[
[
828,
21,
28847
],
[
28847,
60,
868
]
],
[
[
828,
24,
578
],
[
578,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Oxycodone (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and... |
DB01149 | DB01218 | 851 | 1,493 | [
"DDInter1274",
"DDInter852"
] | Nefazodone | Halofantrine | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
851,
25,
1493
]
],
[
[
851,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
851,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
851,
63,
770
],
[
770,... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Nefazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halof... | Nefazodone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Nefazodone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Nefazodone may cause a moderate interaction that could exacerbate diseases when ta... |
DB00238 | DB01129 | 188 | 379 | [
"DDInter1285",
"DDInter1559"
] | Nevirapine | Rabeprazole | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
188,
24,
379
]
],
[
[
188,
6,
8374
],
[
8374,
45,
379
]
],
[
[
188,
21,
29267
],
[
29267,
60,
379
]
],
[
[
188,
24,
1468
],
[
1468,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rabeprazole (Compound)
Nevirapine (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Rabeprazole (Compound)
Nevirapine may cause a moderate interaction that could exa... |
DB06081 | DB10672 | 1,046 | 297 | [
"DDInter286",
"DDInter417"
] | Caplacizumab | Clove | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
1046,
23,
297
]
],
[
[
1046,
25,
235
],
[
235,
62,
297
]
],
[
[
1046,
25,
578
],
[
578,
23,
297
]
],
[
[
1046,
64,
1564
],
[
1564,
... | [
[
[
"Caplacizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
... | Caplacizumab may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Caplacizumab may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interaction ... |
DB00862 | DB01064 | 1,005 | 1,148 | [
"DDInter1918",
"DDInter987"
] | Vardenafil | Isoprenaline | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1005,
24,
1148
]
],
[
[
1005,
24,
480
],
[
480,
24,
1148
]
],
[
[
1005,
21,
28717
],
[
28717,
60,
1148
]
],
[
[
1005,
24,
1151
],
[
11... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Vardenafil (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Isoprenaline (Comp... |
DB00981 | DB09488 | 1,528 | 103 | [
"DDInter1463",
"DDInter23"
] | Physostigmine (ophthalmic) | Acrivastine | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1528,
24,
103
]
],
[
[
1528,
63,
1405
],
[
1405,
24,
103
]
],
[
[
1528,
24,
1443
],
[
1443,
24,
103
]
],
[
[
1528,
24,
1536
],
[
1536,... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acri... |
DB00877 | DB01126 | 629 | 1,260 | [
"DDInter1678",
"DDInter611"
] | Sirolimus | Dutasteride | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Moderate | 1 | [
[
[
629,
24,
1260
]
],
[
[
629,
24,
284
],
[
284,
40,
1260
]
],
[
[
629,
6,
7524
],
[
7524,
45,
1260
]
],
[
[
629,
21,
29023
],
[
29023,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Finasteride"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Finasteride and Finasteride (Compound) resembles Dutasteride (Compound)
Sirolimus (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Dutasteride (Compound)
Sirolimus (Compound) causes Neoplasm malignant (Side Effect) and... |
DB00280 | DB09156 | 494 | 777 | [
"DDInter575",
"DDInter964"
] | Disopyramide | Iopromide | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
494,
24,
777
]
],
[
[
494,
24,
1287
],
[
1287,
25,
777
]
],
[
[
494,
25,
485
],
[
485,
25,
777
]
],
[
[
494,
24,
1287
],
[
1287,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may lead to a major life threatening interaction when taken with Iopromide
Disopyramide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to ... |
DB00607 | DB08899 | 1,249 | 129 | [
"DDInter1256",
"DDInter649"
] | Nafcillin | Enzalutamide | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1249,
24,
129
]
],
[
[
1249,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1249,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1249,
62,
608
],
[
608,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nafcillin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Nafcillin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocain... |
DB00312 | DB06335 | 1,023 | 761 | [
"DDInter1423",
"DDInter1646"
] | Pentobarbital | Saxagliptin | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
1023,
24,
761
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
761
]
],
[
[
1023,
21,
28722
],
[
28722,
60,
761
]
],
[
[
1023,
24,
1491
],
[
1491... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Comp... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Pentobarbital (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin an... |
DB00539 | DB06717 | 11 | 875 | [
"DDInter1837",
"DDInter778"
] | Toremifene | Fosaprepitant | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
11,
24,
875
]
],
[
[
11,
24,
723
],
[
723,
1,
875
]
],
[
[
11,
21,
29122
],
[
29122,
60,
875
]
],
[
[
11,
63,
1101
],
[
1101,
23... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Toremifene (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Fosaprepitant (Compound)
Toremifene may c... |
DB01244 | DB11348 | 762 | 1,065 | [
"DDInter192",
"DDInter279"
] | Bepridil | Calcium Phosphate | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
762,
24,
1065
]
],
[
[
762,
23,
1135
],
[
1135,
23,
943
],
[
943,
63,
1065
]
],
[
[
762,
25,
1456
],
[
1456,
24,
943
],
[
943,
63,
... | [
[
[
"Bepridil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Bepri... |
DB00030 | DB00603 | 1,685 | 303 | [
"DDInter934",
"DDInter1137"
] | Insulin human | Medroxyprogesterone acetate | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
1685,
24,
303
]
],
[
[
1685,
24,
167
],
[
167,
1,
303
]
],
[
[
1685,
24,
1561
],
[
1561,
40,
303
]
],
[
[
1685,
24,
215
],
[
215,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydr... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compoun... |
DB00348 | DB00776 | 254 | 1,335 | [
"DDInter1300",
"DDInter1360"
] | Nitisinone | Oxcarbazepine | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Moderate | 1 | [
[
[
254,
24,
1335
]
],
[
[
254,
24,
126
],
[
126,
1,
1335
]
],
[
[
254,
24,
1264
],
[
1264,
63,
1335
]
],
[
[
254,
23,
307
],
[
307,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Oxcarbazepine (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacer... |
DB00637 | DB09104 | 1,557 | 286 | [
"DDInter128",
"DDInter1118"
] | Astemizole | Magnesium hydroxide | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1557,
24,
286
]
],
[
[
1557,
24,
401
],
[
401,
23,
286
]
],
[
[
1557,
64,
752
],
[
752,
23,
286
]
],
[
[
1557,
63,
355
],
[
355,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Astemizole may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine... |
DB06723 | DB08826 | 115 | 1,292 | [
"DDInter58",
"DDInter489"
] | Aluminum hydroxide | Deferiprone | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Moderate | 1 | [
[
[
115,
24,
1292
]
],
[
[
115,
21,
28643
],
[
28643,
60,
1292
]
],
[
[
115,
24,
428
],
[
428,
63,
1292
]
],
[
[
115,
63,
72
],
[
72,
... | [
[
[
"Aluminum hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Aluminum hydroxide",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Sid... | Aluminum hydroxide (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Deferiprone (Compound)
Aluminum hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate interaction that could exacerbate dis... |
DB00637 | DB06595 | 1,557 | 1,491 | [
"DDInter128",
"DDInter1214"
] | Astemizole | Midostaurin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1557,
24,
1491
]
],
[
[
1557,
23,
112
],
[
112,
23,
1491
]
],
[
[
1557,
24,
888
],
[
888,
24,
1491
]
],
[
[
1557,
24,
1017
],
[
1017,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamo... |
DB10316 | DB15091 | 334 | 676 | [
"DDInter1248",
"DDInter1901"
] | Mumps virus strain B level jeryl lynn live antigen | Upadacitinib | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
334,
25,
676
]
],
[
[
334,
64,
1184
],
[
1184,
25,
676
]
],
[
[
334,
25,
76
],
[
76,
25,
676
]
],
[
[
334,
63,
617
],
[
617,
25,... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when... |
DB00687 | DB01097 | 870 | 1,377 | [
"DDInter747",
"DDInter1033"
] | Fludrocortisone | Leflunomide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
870,
25,
1377
]
],
[
[
870,
21,
29488
],
[
29488,
60,
1377
]
],
[
[
870,
24,
949
],
[
949,
63,
1377
]
],
[
[
870,
63,
240
],
[
240,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Rash maculo-papular"
],
[
"Rash maculo-papular",
"{u} (Side... | Fludrocortisone (Compound) causes Rash maculo-papular (Side Effect) and Rash maculo-papular (Side Effect) is caused by Leflunomide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetan... |
DB00065 | DB00361 | 581 | 134 | [
"DDInter923",
"DDInter1939"
] | Infliximab | Vinorelbine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction of third... | Major | 2 | [
[
[
581,
25,
134
]
],
[
[
581,
25,
147
],
[
147,
63,
134
]
],
[
[
581,
24,
151
],
[
151,
63,
134
]
],
[
[
581,
25,
1101
],
[
1101,
2... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinorelbine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u... | Infliximab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/... |
DB00328 | DB13074 | 831 | 877 | [
"DDInter921",
"DDInter1110"
] | Indomethacin | Macimorelin | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
831,
24,
877
]
],
[
[
831,
24,
1479
],
[
1479,
24,
877
]
],
[
[
831,
40,
1263
],
[
1263,
24,
877
]
],
[
[
831,
24,
477
],
[
477,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Indomethacin (Compound) resembles Bromfenac (Compound) and Bromfenac may cause a moderate... |
DB00880 | DB11827 | 359 | 433 | [
"DDInter360",
"DDInter669"
] | Chlorothiazide | Ertugliflozin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
359,
24,
433
]
],
[
[
359,
40,
811
],
[
811,
24,
433
]
],
[
[
359,
24,
959
],
[
959,
24,
433
]
],
[
[
359,
63,
251
],
[
251,
24,... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may caus... | Chlorothiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction t... |
DB00526 | DB10276 | 1,555 | 1,624 | [
"DDInter1355",
"DDInter1623"
] | Oxaliplatin | Rotavirus vaccine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1555,
25,
1624
]
],
[
[
1555,
63,
552
],
[
552,
25,
1624
]
],
[
[
1555,
24,
1307
],
[
1307,
25,
1624
]
],
[
[
1555,
25,
770
],
[
770,
... | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"C... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may... |
DB00434 | DB01192 | 13 | 560 | [
"DDInter459",
"DDInter1372"
] | Cyproheptadine | Oxymorphone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
13,
24,
560
]
],
[
[
13,
24,
828
],
[
828,
1,
560
]
],
[
[
13,
63,
421
],
[
421,
1,
560
]
],
[
[
13,
21,
28817
],
[
28817,
60,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Oxymorpho... |
DB00444 | DB00609 | 63 | 595 | [
"DDInter1765",
"DDInter694"
] | Teniposide | Ethionamide | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Moderate | 1 | [
[
[
63,
24,
595
]
],
[
[
63,
7,
16640
],
[
16640,
46,
595
]
],
[
[
63,
18,
6584
],
[
6584,
57,
595
]
],
[
[
63,
21,
28787
],
[
28787,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Teniposide",
"{u} (Compound) upregulates {v} (Gene)",
"NUDT9"
],
[
"NUDT9",
"{u} (Gene) is upregulated by {v} (... | Teniposide (Compound) upregulates NUDT9 (Gene) and NUDT9 (Gene) is upregulated by Ethionamide (Compound)
Teniposide (Compound) downregulates SUZ12 (Gene) and SUZ12 (Gene) is downregulated by Ethionamide (Compound)
Teniposide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ethionamid... |
DB00285 | DB00374 | 1,100 | 1,061 | [
"DDInter1927",
"DDInter1852"
] | Venlafaxine | Treprostinil | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
1100,
24,
1061
]
],
[
[
1100,
24,
885
],
[
885,
40,
1061
]
],
[
[
1100,
6,
6017
],
[
6017,
45,
1061
]
],
[
[
1100,
21,
28956
],
[
2895... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Venlafaxine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Treprostinil (Compound)
Venlafaxine (Compound) causes Palpitations (Side Effect)... |
DB00981 | DB01100 | 1,528 | 1,568 | [
"DDInter1463",
"DDInter1470"
] | Physostigmine (ophthalmic) | Pimozide | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Moderate | 1 | [
[
[
1528,
24,
1568
]
],
[
[
1528,
21,
29356
],
[
29356,
60,
1568
]
],
[
[
1528,
63,
19
],
[
19,
24,
1568
]
],
[
[
1528,
24,
830
],
[
830,
... | [
[
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
]
],
[
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Salivary hypersecretion"
],
[
"Salivary hypersecretion",
... | Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Pimozide
Physostigmine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Pimozide (Compound)
Physostigmine may cause a moderate interaction that could exacerbate dis... |
DB01159 | DB09080 | 419 | 144 | [
"DDInter854",
"DDInter1331"
] | Halothane | Olodaterol | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
419,
24,
144
]
],
[
[
419,
25,
1011
],
[
1011,
24,
144
]
],
[
[
419,
64,
11
],
[
11,
24,
144
]
],
[
[
419,
63,
543
],
[
543,
24,... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Halothane may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Halothane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate intera... |
DB06810 | DB11627 | 397 | 1,367 | [
"DDInter1484",
"DDInter860"
] | Plicamycin | Hepatitis B Vaccine (Recombinant) | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
397,
24,
1367
]
],
[
[
397,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
397,
63,
259
],
[
259,
24,
1367
]
],
[
[
397,
25,
375
],
[
375,
... | [
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
... | Plicamycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept an... |
DB01009 | DB05773 | 935 | 1,047 | [
"DDInter1009",
"DDInter1848"
] | Ketoprofen | Trastuzumab emtansine | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
935,
24,
1047
]
],
[
[
935,
24,
848
],
[
848,
24,
1047
]
],
[
[
935,
40,
886
],
[
886,
24,
1047
]
],
[
[
935,
24,
1613
],
[
1613,
... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]... | Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ketoprofen (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction tha... |
DB00197 | DB00397 | 1,324 | 1,466 | [
"DDInter1881",
"DDInter1458"
] | Troglitazone | Phenylpropanolamine | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
1324,
24,
1466
]
],
[
[
1324,
63,
73
],
[
73,
25,
1466
]
],
[
[
1324,
24,
1178
],
[
1178,
63,
1466
]
],
[
[
1324,
24,
1152
],
[
1152,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and T... |
DB00465 | DB09122 | 886 | 1,613 | [
"DDInter1010",
"DDInter1409"
] | Ketorolac | Peginterferon beta-1a | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
886,
24,
1613
]
],
[
[
886,
25,
1274
],
[
1274,
24,
1613
]
],
[
[
886,
24,
1383
],
[
1383,
63,
1613
]
],
[
[
886,
24,
267
],
[
267,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
... | Ketorolac may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodi... |
DB00533 | DB00975 | 1,416 | 1,317 | [
"DDInter1613",
"DDInter573"
] | Rofecoxib | Dipyridamole | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Moderate | 1 | [
[
[
1416,
24,
1317
]
],
[
[
1416,
63,
1031
],
[
1031,
24,
1317
]
],
[
[
1416,
24,
714
],
[
714,
63,
1317
]
],
[
[
1416,
24,
1274
],
[
1274... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Ilop... |
DB00046 | DB00197 | 1,179 | 1,324 | [
"DDInter940",
"DDInter1881"
] | Insulin lispro | Troglitazone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Moderate | 1 | [
[
[
1179,
24,
1324
]
],
[
[
1179,
23,
333
],
[
333,
23,
1324
]
],
[
[
1179,
24,
1101
],
[
1101,
62,
1324
]
],
[
[
1179,
23,
1103
],
[
1103... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
]
],
[
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
],... | Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Troglitazone
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene an... |
DB06605 | DB11718 | 1,409 | 927 | [
"DDInter108",
"DDInter640"
] | Apixaban | Encorafenib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1409,
24,
927
]
],
[
[
1409,
63,
495
],
[
495,
24,
927
]
],
[
[
1409,
64,
998
],
[
998,
24,
927
]
],
[
[
1409,
24,
484
],
[
484,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Apixaban may lead to a major life threatening interaction when taken with Phenylbutazone and Phenylbutazone may cau... |
DB08895 | DB14962 | 976 | 1,363 | [
"DDInter1825",
"DDInter1847"
] | Tofacitinib | Trastuzumab deruxtecan | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
976,
25,
1363
]
],
[
[
976,
63,
1430
],
[
1430,
24,
1363
]
],
[
[
976,
24,
810
],
[
810,
24,
1363
]
],
[
[
976,
25,
384
],
[
384,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Str... |
DB00283 | DB00804 | 701 | 1,507 | [
"DDInter395",
"DDInter543"
] | Clemastine | Dicyclomine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
701,
24,
1507
]
],
[
[
701,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
701,
24,
551
],
[
551,
23,
1507
]
],
[
[
701,
24,
62
],
[
62,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Effe... | Clemastine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may cause a minor interaction that can limit clinical effects when taken wit... |
DB00214 | DB00681 | 1,028 | 1,287 | [
"DDInter1836",
"DDInter85"
] | Torasemide | Amphotericin B | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
1028,
24,
1287
]
],
[
[
1028,
21,
29276
],
[
29276,
60,
1287
]
],
[
[
1028,
63,
600
],
[
600,
23,
1287
]
],
[
[
1028,
24,
86
],
[
86,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Torasemide",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect)... | Torasemide (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Amphotericin B (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with... |
DB00031 | DB00580 | 20 | 311 | [
"DDInter1764",
"DDInter1910"
] | Tenecteplase | Valdecoxib | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
20,
24,
311
]
],
[
[
20,
25,
366
],
[
366,
24,
311
]
],
[
[
20,
25,
500
],
[
500,
63,
311
]
],
[
[
20,
24,
1512
],
[
1512,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Epti... | Tenecteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Valdecoxib
Tenecteplase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moder... |
DB00776 | DB11581 | 1,335 | 1,456 | [
"DDInter1360",
"DDInter1926"
] | Oxcarbazepine | Venetoclax | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1335,
24,
1456
]
],
[
[
1335,
24,
1135
],
[
1135,
23,
1456
]
],
[
[
1335,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
1335,
24,
594
],
[
594... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brig... |
DB06605 | DB14723 | 1,409 | 159 | [
"DDInter108",
"DDInter1026"
] | Apixaban | Larotrectinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1409,
24,
159
]
],
[
[
1409,
63,
222
],
[
222,
23,
159
]
],
[
[
1409,
24,
1375
],
[
1375,
24,
159
]
],
[
[
1409,
62,
307
],
[
307,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamuli... |
DB11560 | DB12141 | 1,678 | 971 | [
"DDInter1038",
"DDInter817"
] | Lesinurad | Gilteritinib | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1678,
24,
971
]
],
[
[
1678,
24,
466
],
[
466,
62,
971
]
],
[
[
1678,
63,
112
],
[
112,
23,
971
]
],
[
[
1678,
63,
1409
],
[
1409,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and M... |
DB00191 | DB00850 | 73 | 1,630 | [
"DDInter1447",
"DDInter1432"
] | Phentermine | Perphenazine | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
73,
24,
1630
]
],
[
[
73,
24,
508
],
[
508,
40,
1630
]
],
[
[
73,
6,
12523
],
[
12523,
45,
1630
]
],
[
[
73,
21,
29232
],
[
29232,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Perphenazine (Compound)
Phentermine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Perphenazine (Compound)
Phentermine (Compound) causes Urticaria (Side Effect) and Urti... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.